Business Context and Reporting Period
Company: Omeros Corporation
Filing Type: Form 8-K (Current Report)
Date of Report: August 8, 2019
Reporting Period: The filing announces financial results for the three and six months ended June 30, 2019.
Key Financial Metrics
The provided text is a cover sheet for the Form 8-K and does not contain specific financial data. It references a press release (Exhibit 99.1) for the actual figures. Consequently, the following metrics are not available in the source text:
- Revenue
- Profit/Loss
- Cash Flow
- Margins
- Debt and Liquidity
Note: The filing text does not provide a clear value for any specific financial metric.
Material Changes
The filing text does not detail specific material changes versus prior periods. It serves solely to notify investors that results for the three and six months ended June 30, 2019, have been issued via a press release.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates by reference a press release dated August 8, 2019, regarding the financial results. No specific commentary, guidance, or outlook is included in the text of the 8-K itself.
Risks and Contingencies: The filing includes a standard disclaimer stating that the information in the Current Report and the accompanying exhibit shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and shall not be incorporated by reference into any other SEC filing.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 8, 2019) for actual revenue, net loss, and cash position figures.
- Verify the specific performance of the company's drug candidates (e.g., OMT-101, OMT-102) as detailed in the referenced press release.
- Confirm the company's cash runway and burn rate, which are critical for a biopharmaceutical firm in development stages.
- Check for any updates on clinical trial timelines or regulatory milestones mentioned in the full press release.